{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:25:18Z","timestamp":1783463118310,"version":"3.55.0"},"reference-count":21,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ACR Open Rheumatology"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Systemic inflammatory conditions affect many women during their reproductive years and tumor necrosis factor inhibitors (TNFi) are one of the most common biologic classes used to help manage disease in this population. Although treatment guidelines now recommend continuing TNFi in pregnancy, studies examining recent real\u2010world treatment trends in this population are limited. The objective of this study was to describe TNFi treatment patterns in the peripregnancy period among patients treated with TNFi before pregnancy, and to describe differences by autoimmune condition, over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted using two US administrative health insurance claims databases: Merative MarketScan Commercial Database (CCAE) and Merative MarketScan Multi\u2010State Medicaid Database (MDCD) between 2010 and 2022. Participants were pregnant women aged 18 to 49 years with \u22651 dispensing for TNFi in the six months before pregnancy start and a diagnosis of psoriasis (PSO), psoriatic arthritis (PsA), ulcerative colitis (UC) or Crohn's disease (CD), and\/or rheumatoid arthritis (RA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 6,031 pregnancies (5,025 women) in CCAE and 825 pregnancies (714 women) in MDCD included. Continuation in pregnancy was highest in UC or CD (89.3% in CCAE and 84.0% in MDCD), followed by RA (71.9% in CCAE and 71.9% in MDCD), and PSO\/PsA (66.6% in CCAE and 65.7% in MDCD). Across all conditions, the proportion continuing TNFi significantly increased over time (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study extends our understanding of peripregnancy TNFi treatment patterns in women with autoimmune diseases, illustrating an increasing trend of TNFi continuation in pregnancy across two administrative data sources in the United States.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr2.90059","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:05:02Z","timestamp":1777446302000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor Necrosis Factor Inhibitor Treatment and Persistence Patterns in the Peripregnancy Period in Patients With Inflammatory Autoimmune Diseases"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6090-491X","authenticated-orcid":false,"given":"Anna","family":"Sheahan","sequence":"first","affiliation":[{"name":"Global Epidemiology Organization, Johnson &amp; Johnson  Raritan New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bozzi","sequence":"additional","affiliation":[{"name":"Global Epidemiology Organization, Johnson &amp; Johnson  Raritan New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica A.","family":"Voss","sequence":"additional","affiliation":[{"name":"Global Epidemiology Organization, Johnson &amp; Johnson  Raritan New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clair","family":"Blacketer","sequence":"additional","affiliation":[{"name":"Global Epidemiology Organization, Johnson &amp; Johnson  Raritan New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Child Health Innovation Leadership Department, Johnson &amp; Johnson  Raritan New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Krumme","sequence":"additional","affiliation":[{"name":"Global Epidemiology Organization, Johnson &amp; Johnson  Raritan New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie H.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Global Epidemiology Organization, Johnson &amp; Johnson  Raritan New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06436-0"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2025.03.016"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208840"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jju006"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39521"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez478"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.10504"},{"key":"e_1_2_7_9_1","unstructured":"OHDSI.OHSDI CommonDataModel [GitHub repository]. GitHub.2026. Accessed March 16 2026.https:\/\/github.com\/OHDSI\/CommonDataModel"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocu023"},{"key":"e_1_2_7_11_1","unstructured":"Janssen CDM Documentation.2026. Accessed March 16 2026.https:\/\/ohdsi.github.io\/ETL-LambdaBuilder\/"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192033"},{"issue":"7","key":"e_1_2_7_13_1","first-page":"756","article-title":"Methodological considerations in estimating adherence and persistence for a long\u2010acting injectable medication","volume":"20","author":"Campagna EJ","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2025-0048"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180226"},{"issue":"2","key":"e_1_2_7_16_1","first-page":"96","article-title":"Pregnancy and inflammatory bowel disease","volume":"11","author":"Hashash JG","year":"2015","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa225"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00279"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.70000"},{"issue":"9","key":"e_1_2_7_20_1","first-page":"145","article-title":"Pregnancy and autoimmune disease","volume":"119","author":"Merz WM","year":"2022","journal-title":"Dtsch Arztebl Int"},{"key":"e_1_2_7_21_1","first-page":"1","article-title":"Characteristics of mothers by source of payment for the delivery: United States, 2021","volume":"468","author":"Valenzuela CP","year":"2023","journal-title":"NCHS Data Brief."},{"key":"e_1_2_7_22_1","unstructured":"U.S. Food & Drug Administration.Evaluating Immunosuppressive Effects of In Utero Exposure to Drug and Biologic Products (Public Workshop).2024. Accessed July 10 2025.https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/evaluating-immunosuppressive-effects-utero-exposure-drug-and-biologic-products-07112024"}],"container-title":["ACR Open Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.90059","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr2.90059","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.90059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T21:57:51Z","timestamp":1783461471000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr2.90059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/acr2.90059"],"URL":"https:\/\/doi.org\/10.1002\/acr2.90059","archive":["Portico"],"relation":{},"ISSN":["2578-5745","2578-5745"],"issn-type":[{"value":"2578-5745","type":"print"},{"value":"2578-5745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"2025-08-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e90059"}}